NovellusDx Tissue Collection Protocol

Fore Biotherapeutics15 enrolled

Overview

NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Patients That Have Been Diagnosed With Colorectal Cancer Patients Eligible for Tumor Biopsy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients that have been diagnosed positive for colon cancer. * available treatment follow up during cancer treatment Exclusion Criteria: * None

Locations (1)

Pathology Lab Hadassah Medical Center

Jerusalem, Israel

Outcomes

Primary Outcomes

Correct identification of tumor mutant genes

Correct identification of tumor mutant genes, in over 85% of the cases

Time frame: up to 12 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.